New analyses from PARADIGM-HF show Novartis’ Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefiting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy.

• The analysis determined that Entresto benefited patients considered clinically stable, with no history or only a remote history of prior heart failure hospitalization, just as much as it did those who were least-stable (heart failure hospitalization within 3 months of baseline)
• For just over half of patients considered clinically stable who experienced an event, the first event was cardiovascular death1
• In a second analysis, patients taking Entresto had about a 20% reduction in CV death or heart failure hospitalization compared to those taking enalapril, regardless of background therapy.

For the full press release, please go here.